OverviewChartProfileKey statisticsFinancialsTechnicalNewsTraderScreen

MORPHOSYS AG O.N./  DE0006632003  /

Xetra
3/29/2023  5:35:10 PM Chg. +0.265 Volume Bid3/29/2023 Ask3/29/2023 Market Capitalization Dividend Y. P/E Ratio
15.050EUR +1.79% 72,401
Turnover: 1.08 mill.		 -Bid Size: - -Ask Size: - 515.19 mill.EUR 0.00% -
GlobeNewswire 11/10/2021 Royalty Pharma Reports Third Quarter 2021 Results
GlobeNewswire 8/11/2021 Royalty Pharma Reports Second Quarter 2021 Results
GlobeNewswire 6/3/2021 CONSTELLATION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of CNST and Encourages Investors ...
GlobeNewswire 6/2/2021 Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys
GlobeNewswire 4/27/2020 I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Mu...
GlobeNewswire 10/28/2019 MOR106 clinical development in atopic dermatitis stopped for futility
GlobeNewswire 4/23/2019 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire 4/23/2019 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire 1/31/2019 Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
GlobeNewswire 9/13/2018 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire 9/13/2018 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire 9/12/2018 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire 9/12/2018 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire 7/19/2018 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire 7/19/2018 Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atop...
GlobeNewswire 7/19/2018 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire 5/1/2018 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire 5/1/2018 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire 4/19/2018 Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market
GlobeNewswire 2/17/2018 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...
GlobeNewswire 2/17/2018 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...
GlobeNewswire 9/27/2017 Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...
GlobeNewswire 9/27/2017 Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...
GlobeNewswire 8/31/2017 Aptevo Therapeutics and MorphoSys End Joint Development and Commercialization Agreement for MOR209/E...
GlobeNewswire 12/15/2016 Aptevo Therapeutics Amends Collaboration Agreement with MorphoSys AG for Novel Immunotherapeutic, MO...